135 related articles for article (PubMed ID: 35992543)
1. PD-L1 rs2890658 Polymorphism Increases Risk for Non-Small-Cell Lung Cancer in Northern China Population Based on Experimental Data and Meta-Analysis.
Wang G; Dong Y; Yang Y; Zhang W; Liu N; Wei Y
Contrast Media Mol Imaging; 2022; 2022():8433489. PubMed ID: 35992543
[TBL] [Abstract][Full Text] [Related]
2. Association between single nucleotide polymorphism of PD-L1 gene and non-small cell lung cancer susceptibility in a Chinese population.
Chen YB; Mu CY; Chen C; Huang JA
Asia Pac J Clin Oncol; 2014 Jun; 10(2):e1-6. PubMed ID: 23167931
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-1 ligand-1 gene rs2890658 polymorphism associated with the risk of esophageal squamous cell carcinoma in smokers.
Zhou RM; Li Y; Liu JH; Wang N; Huang X; Cao SR; Shan BE
Cancer Biomark; 2017 Dec; 21(1):65-71. PubMed ID: 29060926
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer.
Cheng S; Zheng J; Zhu J; Xie C; Zhang X; Han X; Song B; Ma Y; Liu J
Int J Biol Markers; 2015 Nov; 30(4):e364-8. PubMed ID: 26349666
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women.
Karami S; Sattarifard H; Kiumarsi M; Sarabandi S; Taheri M; Hashemi M; Bahari G; Ghavami S
Asian Pac J Cancer Prev; 2020 Oct; 21(10):3115-3123. PubMed ID: 33112575
[TBL] [Abstract][Full Text] [Related]
6. Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population.
Xie Q; Chen Z; Xia L; Zhao Q; Yu H; Yang Z
Gene; 2018 Oct; 674():188-194. PubMed ID: 29940275
[TBL] [Abstract][Full Text] [Related]
7. [Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy].
Zhang GW; Cheng RR; Zhang FR; Li P; Chu HY; Song XJ; Zhang GJ
Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(34):2682-2688. PubMed ID: 32921017
[No Abstract] [Full Text] [Related]
8. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
9. Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract][Full Text] [Related]
10. Common inherited variants of PDCD1, CD274 and HAVCR2 genes differentially modulate the risk and prognosis of adenocarcinoma and squamous cell carcinoma.
Moksud N; Wagner M; Pawełczyk K; Porębska I; Muszczyńska-Bernhard B; Kowal A; Wiśniewski A; Kosacka M; Kończak J; Karpiński P; Frydryk D; Andrzejczak A; Karabon L; Kuśnierczyk P; Jasek M
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6381-6390. PubMed ID: 36759392
[TBL] [Abstract][Full Text] [Related]
11. Case-Control Study on Impact of the Telomerase Reverse Transcriptase Gene Polymorphism and Additional Single Nucleotide Polymorphism (SNP)- SNP Interaction on Non-Small Cell Lung Cancers Risk in Chinese Han Population.
Xing YL; Liu F; Li JF; Lin JC; Zhu GD; Li M; Zhang CR; Niu YY
J Clin Lab Anal; 2016 Nov; 30(6):1071-1077. PubMed ID: 27154632
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.
Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Yoshida H; Yagi Y; Sakamori Y; Nagai H; Hirai T; Kim YH
Sci Rep; 2017 Mar; 7():45124. PubMed ID: 28332580
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
Yoshida H; Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Ajimizu H; Yamazoe M; Kuninaga K; Ogimoto T; Hosoya K; Itotani R; Sakamori Y; Kim YH; Hirai T
Eur J Cancer; 2021 Feb; 144():317-325. PubMed ID: 33385948
[TBL] [Abstract][Full Text] [Related]
14. Association of PD-L1 gene rs4143815 C>G polymorphism and human cancer susceptibility: A systematic review and meta-analysis.
Zou J; Wu D; Li T; Wang X; Liu Y; Tan S
Pathol Res Pract; 2019 Feb; 215(2):229-234. PubMed ID: 30552042
[TBL] [Abstract][Full Text] [Related]
15. The association of PD-L1 gene polymorphisms with non-small-cell lung cancer susceptibility and clinical outcomes in a Chinese population.
Zhao X; Peng Y; Li X; Zhang S; Peng Y; Shan J; Li M; Dai N; Feng Y; Xu C; Wang D
Int J Clin Exp Pathol; 2020; 13(8):2130-2136. PubMed ID: 32922610
[TBL] [Abstract][Full Text] [Related]
16. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
Dietel M; Savelov N; Salanova R; Micke P; Bigras G; Hida T; Antunez J; Guldhammer Skov B; Hutarew G; Sua LF; Akita H; Chan OSH; Piperdi B; Burke T; Khambata-Ford S; Deitz AC
Lung Cancer; 2019 Aug; 134():174-179. PubMed ID: 31319978
[TBL] [Abstract][Full Text] [Related]
17. Association between the telomerase reverse transcriptase (TERT) rs2736098 polymorphism and cancer risk: evidence from a case-control study of non-small-cell lung cancer and a meta-analysis.
Wu H; Qiao N; Wang Y; Jiang M; Wang S; Wang C; Hu L
PLoS One; 2013; 8(11):e76372. PubMed ID: 24260099
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
Zheng Q; Huang Y; Zeng X; Chen X; Shao S; Jin Y; Xue Q; Wang Y; Guo Y; Gu B; Wu C; Li Y
J Cancer Res Clin Oncol; 2021 May; 147(5):1547-1556. PubMed ID: 33196892
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Lee SY; Jung DK; Choi JE; Jin CC; Hong MJ; Do SK; Kang HG; Lee WK; Seok Y; Lee EB; Jeong JY; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Sci Rep; 2016 May; 6():25952. PubMed ID: 27181838
[TBL] [Abstract][Full Text] [Related]
20. [Correlation of matrix metalloproteinase-3 polymorphism to genetic susceptibility and lymph node metastasis of non-small cell lung cancer].
Fang SM; Jin X; Li Y; Wang R; Guo W; Wang N; Zhang JH
Ai Zheng; 2005 Mar; 24(3):305-10. PubMed ID: 15757531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
